By Yash Yadav
Australia’s TGA (Therapeutic Goods Administration) said on January 17:
“Today, the TGA determined that an additional COVID-19 vaccine, the two-dose course of the Gamaleya Institute vaccine (Sputnik V, Russian Federation) would be `recognized` for the purpose of establishing a traveller`s vaccination status”.
Additional data on the Russian vaccine’s performance revealed that two doses of Sputnik V had an average efficacy of 89 percent against symptomatic COVID-19 infection and 98-100 percent against hospitalisation or death, according to the regulator.
“The single-dose course of the Gamaleya vaccine (`Sputnik Light`) is not currently recognized by the TGA,” the Australian regulator specified.
Read all the Latest News here. Follow us on Facebook, Twitter, Instagram, and LinkedIn.